Skip to main content

Table 2 Percentages of EBV specific CTLs in 19 patients at + 30, + 60, and + 90 days after haplo-HSCT and in healthy controls

From: Immune reconstitution of HLA-A*0201/BMLF1- and HLA-A*1101/LMP2-specific Epstein Barr virus cytotoxic T lymphocytes within 90 days after haploidentical hematopoietic stem cell transplantation

Groups

Patients/healthy controls (NO.)

Percentages at + 30 days

Percentages at + 60 days

Percentages at + 90 days

HLA-A*0201 group

    
 

P1

0.1982

2.9100

1.0950

 

P2

0.8337

1.9200

1.3644

 

P3

0.7296

3.0000

1.0119

 

P4

0.3252

3.1700

1.4483

 

P5

0.0179

1.9000

1.1990

 

P6

1.0790

4.2400

 

P7

0.5619

0.6900

 

P8

0.2727

0.5300

 

P9

0.9600

0.5500

 

P10

0.8924

 

H1

2.1000

  
 

H2

0.6200

  
 

H3

1.5900

  
 

H4

5.7900

  
 

H5

1.7700

  
 

H6

0.3000

  
 

H7

2.8800

  
 

H8

1.4700

  
 

H9

3.4800

  

HLA-A*1101 group

    
 

P1

2.4667

0.0672

 

P2

0.3413

0.5073

0.4926

 

P3

0.1585

0.3339

0.3434

 

P4

1.2534

1.5635

1.0086

 

P5

1.0931

2.8223

1.1053

 

P6

0.2601

0.5272

 

P7

0.6569

0.7229

0.4940

 

P8

0.5787

1.0769

 

P9

0.1537

0.8800

1.8715

 

H1

3.5392

  
 

H2

0.7454

  
 

H3

2.1402

  
 

H4

3.5406

  
 

H5

2.0589

  
 

H6

2.7509

  
 

H7

6.1721

  
 

H8

0.6712

  
 

H9

2.7146

  
 

H10

2.6164

  
 

H11

0.7193

  
 

H12

1.4663

  
 

H13

0.9191

  
 

H14

6.6107

  
 

H15

3.5822

  
 

H16

3.5711

  
 

H17

2.2981

  
 

H18

2.6966

  
 

H19

2.8326

  
  1. Abbreviations: P patient, H healthy controls. The percentages of EBV specific CTLs of healthy controls were detected at only one-time point during our study